Liver Disease Diagnosis and Treatment

Liver Viscosity Decreases Before the Onset of Fibrosis in Metabolic Dysfunction-Associated 1 Steatohepatitis (MASH)

This study shows that liver viscosity decreases before fibrosis in a mouse model of MASH, indicating it as a potential early biomarker.

Glucagon-induced PGC-1α4/PPARγ promotes hepatic lipid storage and macrosteatosis in fasting and MASLD

Totum-448, a polyphenol-rich plant extract, decreases hepatic steatosis and inflammation in diet-induced MASLD mice

Totum-448 reduces hepatic steatosis and inflammation in diet-induced MASLD mice without affecting body weight or microbiota.

iPSC-Derived Hepatocytes from Patients with MASLD Exhibit Early Mitochondrial Dysfunction

This study shows that iPSC-derived hepatocytes from MASLD patients show early mitochondrial dysfunction, including reduced oxygen consumption and increased ROS production, independent of PNPLA3 genotype.

Ablation of hepatocyte derived-FGL1 does not aggravate metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma

This study shows that ablating FGL1 in hepatocytes does not worsen MASLD or HCC, despite increased glucose and metabolic changes in western diet-fed mice.

Effect of thermoneutral housing on MASLD severity, hepatic gene expression, and BAT activation during β3-adrenergic stimulation in mice

This study shows thermoneutral housing worsens MASLD in mice by increasing obesity, inflammation, fibrosis, and impairing BAT activation during β3-adrenergic stimulation.

MTARC1 Regulates Lipid Droplet Degradation via Phospholipid Remodeling in Metabolic Fatty Liver Disease

This study shows MTARC1 inactivation reduces hepatic triglyceride accumulation and liver injury by promoting lipid droplet degradation through phospholipid remodeling.

ORP2 regulates free cholesterol accumulation in hepatocytes during MASH

This study shows that ORP2 prevents free cholesterol accumulation in mouse liver, and its absence leads to severe MASH with cholesterol crystals.

Exercise alleviates liver senescence but does not outmatch the effect of dietary restriction in diet-induced MASLD

This study compares the effects of aerobic exercise and dietary restriction on liver senescence in mice with diet-induced MASLD, finding that dietary restriction is more effective than exercise alone.

The SAMM50 rs3761472 causes mitochondrial dysfunction and metabolic dysfunction-associated steatotic liver disease

This study identifies SAMM50 rs3761472 as a risk factor for MASLD by showing it causes mitochondrial dysfunction and metabolic impairments in mice.

Chitinase-1 inhibition reverses metabolic dysregulation and restores homeostasis in MASH animal models

This study shows that inhibiting chitinase-1 with OATD-01 reverses metabolic dysregulation and restores homeostasis in MASH animal models.

Feeding induces c-Fos in hepatocytes contributing to hepatocellular carcinoma in obesity

This study shows that c-Fos in hepatocytes promotes MASLD and HCC by altering metabolic pathways and signaling networks in obesity.

Hepatocyte-specific CLSTN3B ablation impairs lipid droplet maturation and alleviates diet-induced steatohepatitis in mice

This study shows that CLSTN3B promotes lipid droplet maturation in hepatocytes and that its deletion reduces steatohepatitis in mice, with a positive correlation between CLSTN3B expression and MASLD severity in humans.

The ferroptosis mediator ACSL4 fails to prevent disease progression in mouse models of MASLD

This study investigates whether ACSL4 deletion in liver cells prevents MASLD progression in mice but finds no significant differences compared to wild-type mice.

Therapeutic Activity of Resolvin D1 (RvD1) in Murine MASH

This study investigates how RvD1 reduces inflammation, cell death, and fibrosis in MASH by targeting Stat1, ER stress, and MMP pathways.

Single cell multiomics reveals drivers of metabolic dysfunction-associated steatohepatitis

This study uses single-cell multi-omics to identify cell type-specific regulatory networks and novel therapeutic targets in MASLD.

Differential Regulation of Hepatic Macrophage Fate by Chi3l1 in MASLD

This study identifies Chi3l1 as a metabolic regulator that differentially affects hepatic macrophage fate in MASLD by modulating glucose metabolism in Kupffer cells.

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis

Cholesterol accumulation in hepatic lipid droplets drives inflammation and fibrosis in mouse and human MASH and is reversed by inhibiting cholesterol synthesis or knocking down Coasy or Hsd17b13.

Intercellular adhesion molecule-1 protects against adipose tissue inflammation and insulin resistance but promotes liver inflammation and hepatic fibrosis in mice

This study shows ICAM-1 protects against adipose tissue inflammation and insulin resistance but worsens liver inflammation and fibrosis in mice with diet-induced obesity.

Mitochondrial Dysfunction Induces Hepatic Lipid Accumulation and Inflammatory Responses in mtDNA Mutator Mice

This study shows mitochondrial dysfunction causes liver lipid accumulation and inflammation in mtDNA mutator mice without obesity or insulin resistance.

PNPLA3 I148M Reduces Hepatic Triacylglycerol Secretion and Mitigates Left Ventricular Diastolic Dysfunction in MASH Diet Mice

This study shows that PNPLA3-I148M reduces hepatic TAG secretion and protects against cardiac diastolic dysfunction in MASH diet mice, despite promoting liver steatosis.

Ketogenesis protects against MASLD-MASH progression through mechanisms that extend beyond overall fat oxidation rate

Induction of TFEB promotes Kupffer cell survival and reduces lipid accumulation and inflammation in MASLD

This study shows that inducing TFEB in Kupffer cells reduces cell death, lipid accumulation, and inflammation in MASLD.

Green Jackfruit Flour Prevents Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma via the AMPK and MAPK Signaling Pathways

This study shows that green jackfruit flour reduces MASH and HCC in mice by activating AMPK and inhibiting MAPK pathways through microbial fermentation products.

Targeting CRM1-HMGB1 Nuclear Translocation in Type 2 Diabetes-Driven Metabolic Dysfunction Associated Steatotic Liver Disease

This study investigates the role of CRM1/HMGB1 nuclear translocation in T2D-driven MASLD and shows that inhibiting this pathway reduces HMGB1 release in T2D-NASH.

AMPK-activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching

This study shows that ATX-304, an AMPK activator, reduces oxidative stress and improves MASLD in mice by altering liver metabolism and lipid distribution.

Mechanistic basis for protection against fatty liver disease by CIDEB loss-of-function mutations

This study investigates how CIDEB loss-of-function mutations protect against fatty liver disease by enhancing β-oxidation through ATGL and PPARα activation.

p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis

This study shows that p53 and TIGAR protect against MASH by controlling redox balance, preventing ROS accumulation, fibrosis, and inflammation.

Spatial Transcriptomic Signature of Progressive Fibrosis in Human MASLD: Role of Senescence and Metabolic Reprogramming.

This study uses spatial transcriptomics to analyze liver fibrosis stages in MASLD, identifying metabolic reprogramming and senescence signatures linked to fibrosis progression.

Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease

This study identifies protein biomarkers for MASLD using proteomics data from liver, blood, and adipose tissue, showing improved prediction models over existing methods.